Translate Bio (NASDAQ:TBIO) and Osiris Therapeutics (OTCMKTS:OSIR) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, dividends, risk, analyst recommendations and earnings.
This table compares Translate Bio and Osiris Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
87.7% of Translate Bio shares are owned by institutional investors. Comparatively, 0.3% of Osiris Therapeutics shares are owned by institutional investors. 15.4% of Translate Bio shares are owned by insiders. Comparatively, 43.4% of Osiris Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
This is a breakdown of recent ratings and recommmendations for Translate Bio and Osiris Therapeutics, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Translate Bio presently has a consensus price target of $20.75, suggesting a potential upside of 171.60%. Given Translate Bio’s higher possible upside, equities analysts plainly believe Translate Bio is more favorable than Osiris Therapeutics.
Earnings & Valuation
This table compares Translate Bio and Osiris Therapeutics’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Translate Bio||$1.42 million||322.92||-$97.39 million||($3.64)||-2.10|
Osiris Therapeutics has lower revenue, but higher earnings than Translate Bio.
About Translate Bio
Translate Bio, Inc., a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 to treat ornithine transcarbamylase deficiency. It has a collaboration and license agreement with Sanofi Pasteur Inc. to develop mRNA vaccines for up to five infectious disease pathogens. The company was formerly known as RaNA Therapeutics, Inc. and changed its name to Translate Bio, Inc. in June 2017. Translate Bio, Inc. was founded in 2011 and is headquartered in Lexington, Massachusetts.
About Osiris Therapeutics
Osiris Therapeutics, Inc. researches, develops, manufactures, markets, and distributes regenerative medicine products in the United States. Its products include Grafix and Stravix for treating chronic wounds of diabetic foot ulcers, venous leg ulcers, pressure ulcers, arterial ulcers, and severe burns, as well as surgical and trauma wounds; BIO4 for bone repair and regeneration in spine, trauma, extremity, cranial, and foot and ankle surgeries; and Cartiform for treating articular cartilage lesions in the knee and other joints. The company also develops and markets Menvivo for the repair of meniscus; and TruSkin for treating chronic wounds. It markets and distributes its products directly to physicians, hospitals, and other healthcare providers, as well as through agents and distributors. Osiris Therapeutics, Inc. was founded in 1992 and is headquartered in Columbia, Maryland.
Receive News & Ratings for Translate Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Translate Bio and related companies with MarketBeat.com's FREE daily email newsletter.